Mirati announces CEO resignation, then a $250M public offering after disclosing clinical plans

David Meek, the CEO of Mirati Therapeutics, has resigned from the biotech and its board, the San Diego drug developer said Tuesday after the markets closed.

Minutes later, Mirati also announced plans for a $250 million public offering, with $37.5 million more…
Click here to view original post